Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Prothena Corporation plc (NASDAQ:PRTA) is an Ireland-based late-stage clinical biotechnology company that identifies and ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

Whyte, 18, a popular Tiktok creator, had 100,00 followers and his account was flooded with over 4,000 comments in the days after his death, including many wishing him a heavenly 19th birthday on ...

Featuring works from Chelsea Odufu, Laurena Finéus, Jarrett Key, and more, the show challenges how we encounter personal ...

In late May, Saanich student Nathan Hellner-Mestelman received the TD Scholarship for Community Leadership – an award coveted ...

Shares of Roche drew increased retail attention Monday after the Swiss drugmaker said it would move its investigational ...

An ESSENCE beauty editor prefers pharmacy skincare over expensive, buzzword products—here's why.

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...